17:37 , May 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Taxifolin could treat cerebral amyloid angiopathy

DISEASE CATEGORY: Neurology INDICATION: Alzheimer's disease (AD) Mouse studies suggest the flavonoid natural product taxifolin could help treat cerebral amyloid angiopathy (CAA), a vascular complication of AD. In a mouse model of CAA, taxifolin decreased...
17:36 , May 4, 2018 |  BC Week In Review  |  Clinical News

Merck's verubecestat reduces beta amyloid levels but fails to improve cognition, function

Data published in the New England Journal of Medicine from the discontinued Phase II/III EPOCH trial in 1,958 patients with mild to moderate Alzheimer's disease showed that verubecestat (MK-8931) from Merck & Co. Inc. (NYSE:MRK)...
17:11 , Feb 6, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cell-free assays; plasma markers A composite measure of Aβ 40 , Aβ 42 and APP 669-711 levels in plasma that determines the brain burden of β amyloid could help stratify AD and MCI patients...
22:50 , Feb 2, 2018 |  BC Extra  |  Preclinical News

Plasma biomarker may aid AD diagnosis

In a study published in Nature , Japanese researchers identified a plasma biomarker of brain beta amyloid burden that had an accuracy of about 90% compared against PET imaging, offering the possibility of cheaper and...
00:53 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Mouse studies identified a prodrug of a TrkB agonist that could help treat AD. Chemical synthesis and testing in mouse-based PK assays of prodrugs of a 7,8-dihydroxyflavone-based TrkB agonist yielded a...
20:54 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Mouse studies suggest antisense oligonucleotides (ASOs) targeting the APOE variant APOE4 could help treat AD. In a mouse model of AD, intracerebroventricular injection of an ASO targeting APOE4 decreased β amyloid...
22:03 , Oct 6, 2017 |  BC Extra  |  Preclinical News

New light on gamma secretase failures in AD

In a study published in Cell Reports this week, researchers from Osaka University added another possible explanation for why gamma secretase /presenilin inhibitors have failed in Alzheimer’s disease trials. The gamma secretase complex acts downstream...
15:01 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Araclon to begin Phase II trial of AD vaccine

This month, Araclon Biotech S.L. (Zaragoza, Spain) plans to begin enrollment in a Phase II trial of ABvac40 to treat patients with "very early stages" of Alzheimer's disease (AD). The placebo-controlled, European trial will establish...
04:28 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

PF-06648671: Ph I data

A double-blind, placebo-controlled, Belgian Phase I trial in 92 healthy volunteers showed that single doses of 150 and 300 mg oral PF-06648671 and once-daily doses of 4-200 mg oral PF-06648671 for 14 days were well...
19:13 , Jan 20, 2017 |  BC Week In Review  |  Clinical News

Neflamapimod: Ph IIa Study 303 data

The double-blind, U.S. Phase IIa Study 303 in 8 evaluable patients ages 60-85 with mild cognitive impairment (MCI) due to AD or mild AD showed that twice-daily 40 and 125 mg oral neflamapimod improved mean...